Answers are grounded in this paper and cite their sources.
Diabetic meibomian gland dysfunction (MGD) is associated with duct obstruction, excessive oxidative stress, chronic inflammation, and disturbed lipid metabolism, which together contribute to progressive gland dysfunction. These interconnected abnormalities make it difficult to achieve effective treatment by targeting a single pathological process. Here, we developed an injectable multifunctional hydrogel for diabetic MGD treatment by integrating complementary therapeutic functions into a thermosensitive PLGA-PEG-PLGA matrix. Dexamethasone (Dex)-loaded mesoporous polydopamine nanoparticles (Dex@mPDA) were incorporated into the hydrogel to provide photothermal, antioxidative, and anti-inflammatory functions. After local administration, the hydrogel formed an in situ depot around the meibomian glands. Upon near-infrared irradiation, mPDA generated mild photothermal heating to liquefy obstructed meibum, while its ROS-scavenging activity reduced oxidative stress and locally delivered Dex suppressed chronic inflammation, thereby remodeling the pathological microenvironment of diabetic MGD. In vitro and in vivo studies demonstrated that the hydrogel reduced the oxidative stress-inflammation cycle, promoted meibocyte differentiation and lipid synthesis, and restored meibomian gland function. In diabetic MGD mice, treatment relieved gland obstruction, preserved gland morphology, restored lipid metabolic homeostasis, and improved tear film stability. Collectively, the injectable hydrogel provides a pathology-guided therapeutic strategy for diabetic MGD and highlights the potential of pathology-guided biomaterial design for treating chronic ocular surface diseases.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: